Last updated: July 31, 2026
Flovent is no longer a durable branded-growth asset in the United States. The product remains clinically established, but its investment profile has shifted from protected branded inhaler to mature respiratory franchise facing generic and authorized-generic substitution. The key assets are fluticasone propionate inhalation aerosol and inhalation powder, marketed as Flovent HFA and Flovent Diskus. GlaxoSmithKline, now GSK plc, has reduced the product’s strategic role as it transitions respiratory revenue toward Trelegy Ellipta, Nucala, and other newer products.
What is Flovent and how does it generate revenue?
Flovent contains fluticasone propionate, an inhaled corticosteroid used for the maintenance treatment of asthma. It is not a rescue medicine and is not indicated for acute bronchospasm. The principal U.S. dosage forms are:
| Product |
Delivery system |
Active ingredient |
Primary U.S. status |
| Flovent HFA |
Pressurized metered-dose inhaler |
Fluticasone propionate |
Mature branded product; GSK discontinued U.S. supply |
| Flovent Diskus |
Dry-powder inhaler |
Fluticasone propionate |
Mature branded product; GSK discontinued U.S. supply |
| Authorized generic equivalents |
HFA and Diskus-related presentations |
Fluticasone propionate |
Distributed following GSK discontinuation |
Flovent’s commercial value historically came from chronic asthma treatment, pediatric use, physician familiarity, and broad formulary access. The product had a large installed base because inhaled corticosteroids are foundational controller medicines.
GSK does not generally report Flovent as a separate current operating segment. U.S. Flovent revenue is embedded within broader respiratory and established-product reporting, limiting the ability to value it as a stand-alone public-company asset. GSK’s reported respiratory portfolio now places greater emphasis on Trelegy Ellipta, Anoro Ellipta, Nucala, and combination products rather than standalone inhaled corticosteroids. [1]
When did Flovent lose exclusivity?
Flovent has lost the exclusivity characteristics that supported premium branded pricing in the United States.
The original Flovent approvals date to the late 1990s for Diskus and the mid-2000s for HFA. The relevant U.S. market has since moved beyond the core patent-protected commercial period. FDA-approved generic and authorized-generic competition has weakened pricing power, while GSK’s decision to discontinue branded U.S. Flovent accelerated the transition.
GSK announced that it would discontinue Flovent HFA and Flovent Diskus in the United States at the end of 2023 and make authorized generic versions available through Prasco Laboratories. The change was effective January 1, 2024. [2]
Flovent exclusivity timeline
| Date |
Event |
| 1998 |
FDA approval of Flovent Diskus |
| 2000s |
Expansion of Flovent HFA strengths and market adoption |
| 2006 |
FDA approval of Flovent HFA |
| 2019-2023 |
Generic and authorized-generic competitive pressure increases |
| End of 2023 |
GSK discontinues branded Flovent HFA and Diskus in the U.S. |
| January 1, 2024 |
Authorized-generic supply becomes the principal continuation pathway |
| 2024 onward |
Commercial value depends primarily on generic economics, supply, contracting, and international sales |
The product’s practical loss of exclusivity occurred before the branded discontinuation. The discontinuation did not create exclusivity; it changed the commercial channel.
What patents protect Flovent?
Flovent’s historic protection involved both active-ingredient rights and inhaler-device, formulation, and manufacturing claims. The commercial protection for inhaled products is often more complex than the protection for an oral tablet because competitors must establish pharmaceutical equivalence, aerodynamic performance, device performance, and manufacturing consistency.
The most relevant protection categories were:
- Fluticasone propionate compound and composition claims.
- Metered-dose aerosol formulations.
- Dry-powder inhalation formulations.
- Inhaler devices and dose-counter systems.
- Particle-size distribution and pulmonary delivery characteristics.
- Manufacturing processes and blend uniformity.
- Method-of-use claims for maintenance treatment of asthma.
The core compound protection is no longer a material commercial barrier. Any remaining patent exposure is more likely to involve device, formulation, process, or specific use claims than the basic identity of fluticasone propionate.
How strong is the Flovent patent estate?
The Flovent patent estate is commercially weak in the United States relative to a newly launched inhaled medicine. Several factors reduce its defensive value:
- The product has been marketed for decades.
- Generic fluticasone propionate inhalation products have entered or approached the market.
- GSK elected to withdraw the branded U.S. products.
- The company is supporting authorized-generic continuity rather than defending a premium branded price.
- Inhaled corticosteroid competition is established across multiple delivery platforms.
Patent strength remains more relevant outside the United States where national patent terms, regulatory pathways, and local generic penetration differ. International rights may also vary by presentation and market.
What is the FDA regulatory status of Flovent?
Flovent was approved through the FDA new drug application pathway. Its U.S. regulatory history includes:
- Flovent Diskus, NDA 020833.
- Flovent HFA, NDA 021433.
- Multiple approved strengths and labeling updates.
- Generic and authorized-generic products regulated under abbreviated new drug applications or equivalent commercial arrangements.
The principal FDA regulatory issue is no longer initial approval. It is substitution and continuity of supply. Inhaled products can face practical barriers beyond chemical equivalence, including dose delivery, device operation, patient technique, and pharmacy substitution rules.
The FDA Orange Book remains relevant for identifying listed patents and regulatory exclusivity associated with approved Flovent products and their reference products. The Orange Book should be evaluated by dosage form and strength because inhaler listings are not necessarily interchangeable across HFA aerosol and dry-powder presentations. [3]
What is the Orange Book status of Flovent?
The Orange Book status is that of a mature reference product with historical patent listings and no meaningful remaining branded exclusivity supporting a new premium launch in the United States.
The critical distinction is between:
- FDA approval of the reference product;
- Orange Book-listed patents;
- enforceable patent term;
- regulatory exclusivity;
- pharmacy-level substitution;
- actual generic availability.
An Orange Book listing does not by itself prevent generic entry after patent expiration, settlement, invalidity, non-infringement, or an authorized-generic arrangement. For Flovent, the commercial evidence is the availability of generic or authorized-generic supply and GSK’s branded discontinuation.
Which companies are challenging Flovent?
The competitive field includes generic inhaler manufacturers and suppliers operating through abbreviated approval pathways or authorized-generic arrangements. Prasco became the principal named U.S. commercial partner for authorized-generic Flovent presentations after GSK’s withdrawal. Other inhaled corticosteroid competitors include:
- Teva Pharmaceutical Industries;
- Hikma Pharmaceuticals;
- Cipla;
- Viatris and legacy Mylan-related respiratory products;
- Generic suppliers of budesonide inhalation products;
- Manufacturers of combination inhaled corticosteroids and long-acting bronchodilators.
Competition is not limited to exact fluticasone propionate equivalents. Asthma patients may be treated with budesonide, beclomethasone, mometasone, fluticasone furoate, or combination products such as fluticasone propionate/salmeterol and fluticasone furoate/vilanterol.
What generic entry risks exist for Flovent?
Generic-entry risk is high and has already been realized.
Direct substitution risk
Authorized-generic and generic fluticasone products can pressure the price of branded Flovent. Once a lower-cost equivalent is available, payers and pharmacy benefit managers have an incentive to move utilization away from the branded product.
Device-switch risk
Flovent HFA and Flovent Diskus are not interchangeable in the practical sense of patient use. Patients must understand inhaler operation, dose counters, priming, cleaning, and inhalation technique. Device differences can slow substitution but do not preserve branded pricing indefinitely.
Contracting risk
GSK’s withdrawal eliminates much of the commercial rationale for maintaining Flovent as a premium brand. The remaining economics are concentrated in manufacturing, supply contracts, distribution, and authorized-generic margins.
Therapeutic substitution risk
Flovent also competes with other inhaled corticosteroids. A payer may prefer a different molecule or device based on formulary rebates, supply, patient age, or clinical policy.
What patent litigation and Paragraph IV challenges affect Flovent?
Flovent’s competitive history includes the type of Paragraph IV activity typical for a mature inhaled product. Generic applicants may certify that listed patents are invalid, unenforceable, or not infringed, creating potential litigation under the Hatch-Waxman Act.
The commercial significance of a Paragraph IV challenge depends on:
- the specific Flovent dosage form;
- the patents certified against;
- the timing of the ANDA filing;
- whether GSK files suit within the statutory period;
- the availability of 180-day generic exclusivity;
- the scope of any settlement;
- the existence of an authorized generic.
For a product that GSK has already discontinued, later patent litigation has limited strategic value unless it affects authorized-generic economics, supply rights, or a high-value international market. The key U.S. risk is therefore commercial erosion rather than a new wave of branded litigation.
Are there Flovent settlement agreements?
Publicly material settlement terms should be assessed company by company and product by product. Generic inhaler settlements can include launch dates, supply arrangements, licenses, or authorized-generic provisions. The GSK-Prasco arrangement is commercially more important than a conventional litigation settlement because it provides continuity after branded discontinuation.
A settlement that permits early generic entry can reduce litigation expense but accelerates price erosion. An authorized-generic agreement can preserve some economics for the innovator while transferring volume away from the branded label.
What formulations are protected by Flovent patents?
The most commercially relevant formulations are:
Flovent HFA
Flovent HFA is a pressurized aerosol formulation using hydrofluoroalkane propellant technology. Its commercial protection historically depended on formulation composition, aerosol performance, dose uniformity, canister and actuator configuration, and manufacturing controls.
Flovent Diskus
Flovent Diskus is a dry-powder inhalation product. Relevant technical characteristics include powder blending, particle engineering, moisture control, dispersion, blister packaging, and device performance.
The technical barriers are real but not necessarily durable patent barriers. Generic companies must satisfy FDA requirements for equivalent performance, but device and formulation complexity generally increases development cost rather than preserving long-term exclusivity.
How does Flovent compare with Trelegy and Advair?
| Product |
Main role |
Commercial maturity |
Investment profile |
| Flovent |
Inhaled corticosteroid monotherapy |
Mature and genericized |
Declining, low-growth |
| Advair |
Fluticasone propionate/salmeterol |
Mature combination product |
Generic erosion with residual franchise value |
| Trelegy |
Fluticasone furoate/umeclidinium/vilanterol |
Newer triple therapy |
More important to GSK growth and mix |
| Nucala |
Mepolizumab biologic |
Specialty respiratory |
Higher-value biologic franchise with biosimilar and lifecycle risk |
Trelegy has stronger commercial positioning because it addresses maintenance therapy with triple bronchodilator and corticosteroid treatment. Flovent remains relevant clinically, particularly in patients requiring inhaled corticosteroid monotherapy, but it does not have the same growth characteristics.
What is the revenue exposure for GSK?
Flovent is strategically important as a historical product but is unlikely to be a major incremental earnings driver for GSK after the U.S. branded discontinuation. Its economic contribution is constrained by:
- generic pricing;
- reduced branded volume;
- authorized-generic margins;
- manufacturing and distribution costs;
- international market variation;
- substitution by newer respiratory products.
GSK’s investor thesis depends more heavily on respiratory portfolio growth, vaccines, specialty medicines, and pipeline execution than on Flovent. Flovent’s decline may reduce reported established-product revenue, but it also allows GSK to focus resources on higher-value products.
What are the main investment scenarios for Flovent?
Base case: mature-product runoff
The base case is continued U.S. erosion, with authorized-generic and generic products replacing branded Flovent. GSK retains limited value through supply or licensing economics, while international revenue declines at a slower or uneven rate.
Downside case: rapid substitution and price compression
In the downside scenario, payers accelerate conversion to low-cost alternatives, generic suppliers compete aggressively, and device-related barriers do not materially slow switching. Flovent becomes a low-margin established product with limited strategic value.
Upside case: stable chronic demand and supply discipline
The upside case is limited. Asthma prevalence and clinical familiarity support durable unit demand, while manufacturing complexity can restrict the number of reliable suppliers. That could stabilize volume and margins for authorized-generic products. It would not restore the former branded-exclusivity profile.
What generic launch scenarios should investors model?
Investors should model three variables rather than a conventional patent-cliff date:
- Volume conversion: the percentage of Flovent users moved to generic or authorized-generic products.
- Net price decline: the discount relative to historical branded Flovent pricing.
- Supply concentration: the ability of generic manufacturers to maintain uninterrupted inhaler production.
A reasonable strategic conclusion is that unit demand can remain substantial while branded revenue falls sharply. Inhaled medicines often retain patient demand after loss of exclusivity, but the value shifts from innovation margin to manufacturing scale and contracting execution.
What geographic markets remain relevant?
The United States is the clearest mature market because generic substitution and branded discontinuation are advanced. Europe, Japan, Canada, and emerging markets may show different timing because of national reimbursement systems, local patent terms, device approvals, and procurement practices.
International Flovent or Flixotide sales may continue under different brand names and market structures. The relevant analysis must separate:
- country-specific patent expiry;
- regulatory approval of local equivalents;
- reimbursement status;
- branded-generic substitution;
- manufacturing location;
- local licensees and distributors.
Key Takeaways
- Flovent is a mature inhaled corticosteroid product with high generic-entry exposure.
- GSK discontinued branded Flovent HFA and Diskus in the U.S. at the end of 2023.
- Prasco authorized-generic supply became the principal U.S. continuity pathway from January 1, 2024.
- The core compound and historical branded exclusivity are no longer meaningful U.S. investment barriers.
- Remaining value depends on authorized-generic economics, manufacturing reliability, and international sales.
- Flovent is less important to GSK’s growth outlook than Trelegy, Nucala, vaccines, and newer specialty medicines.
- The main investment risk is rapid price erosion, not a single future patent-expiry event.
- The main technical barrier is inhaler equivalence and manufacturing consistency, not ownership of a newly differentiated molecule.
FAQs
Is Flovent still available in the United States?
Branded Flovent HFA and Flovent Diskus were discontinued by GSK in the United States at the end of 2023. Authorized-generic versions and other fluticasone propionate inhalation products provide replacement supply.
Is Flovent a biologic with biosimilar risk?
No. Flovent is a small-molecule inhaled corticosteroid product. Its competitive risk comes from generic inhalation products, not biosimilars.
Does Flovent still have patent protection?
Historical formulation, device, and method-of-use patents may remain relevant in particular jurisdictions or product listings, but the U.S. commercial franchise no longer has effective branded exclusivity.
Which GSK product replaces Flovent strategically?
Trelegy Ellipta is more important to GSK’s respiratory growth strategy, although it is a different therapy and is not a direct one-for-one replacement for inhaled corticosteroid monotherapy.
Can generic Flovent be automatically substituted at the pharmacy?
Substitution depends on the specific product, FDA therapeutic-equivalence designation, state law, payer policy, and whether the prescription specifies a particular device. HFA and Diskus products also require different inhaler techniques.
References
-
GSK plc. (2024). Annual report 2023. https://www.gsk.com/en-gb/investors/annual-reports/
-
GSK plc. (2023, October 19). GSK announces discontinuation of Flovent HFA and Flovent Diskus in the United States and availability of authorized generics. GSK investor and media materials.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2023). Flovent HFA prescribing information. https://www.accessdata.fda.gov/
-
U.S. Food and Drug Administration. (2023). Flovent Diskus prescribing information. https://www.accessdata.fda.gov/
